NATALEE 5-Year Outcomes

In this segment, the panel unpacks the 5-year results from the NATALEE trial, which evaluated ribociclib plus a nonsteroidal aromatase inhibitor in early HR+/HER2– breast cancer. The discussion highlights the sustained invasive disease-free survival benefit and the consistency of that benefit across multiple patient subgroups, underscoring the potential role of ribociclib in a broader range of earlier-stage disease. The experts also examine emerging overall survival signals, the reassuring long-term safety profile observed years after treatment completion, and the practical considerations for managing patients throughout an extended adjuvant course. Finally, the segment places NATALEE in the context of longer-term data from other CDK4/6 inhibitors, exploring how these evolving outcomes may reshape treatment selection and follow-up strategies in the adjuvant setting.